Lafond G, Roy P E, Grenier R
Can J Ophthalmol. 1984 Jun;19(4):173-5.
Therapy with methoxsalen and type A (long-wavelength) ultraviolet radiation (PUVA) has recently become a common method of treating psoriasis and other dermatologic conditions. This treatment could induce cataractous changes in the human lens through a reaction between the psoralen in the lens and either UVA or ambient light. In a 28-month-long prospective study of 78 patients treated with PUVA, small lens opacities appeared in 3 patients, aged 67, 48 and 32 years. The two younger patients had not worn their protective glasses for 24 hours after each treatment, as recommended. Therefore, although it cannot be concluded that PUVA therapy caused these opacities, eye protection during treatment and for 24 hours thereafter should be emphasized to the patients.
补骨脂素与A型(长波)紫外线辐射(PUVA)疗法最近已成为治疗银屑病和其他皮肤病的常用方法。这种治疗可能通过晶状体中的补骨脂素与紫外线A或环境光之间的反应,在人晶状体中诱发白内障样改变。在一项对78例接受PUVA治疗的患者进行的为期28个月的前瞻性研究中,3例患者(年龄分别为67岁、48岁和32岁)出现了小的晶状体混浊。两名较年轻的患者未按建议在每次治疗后24小时佩戴防护眼镜。因此,虽然不能得出PUVA疗法导致这些混浊的结论,但应向患者强调在治疗期间及之后24小时进行眼部防护。